First report of post-transplant autoimmune hepatitis recurrence following SARS-CoV-2 mRNA vaccination.
Transpl Immunol
; 72: 101600, 2022 06.
Article
in English
| MEDLINE | ID: covidwho-1773822
ABSTRACT
Whilst vaccination for the SARS-CoV-2 virus has been successful in reducing the severity and burden of the COVID-19 pandemic, there have been recent reports of mRNA vaccines triggering autoimmune hepatitis in the native liver. There have been no descriptions thus far of recurrent 'autoimmune hepatitis' after liver transplantation in the context of SARS-CoV-2 vaccination. We describe a patient transplanted for autoimmune hepatitis who was stable for many years until they had immune-mediated flares coinciding with Pfizer-BioNTech mRNA vaccination. Intravenous steroid treatment was required to suppress histologically evident interface hepatitis. We firmly believe that mRNA vaccination was responsible for this 'recurrence' and that clinicians should be vigilant for this reaction in patients transplanted for autoimmune hepatitis.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Hepatitis, Autoimmune
/
COVID-19
Type of study:
Diagnostic study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Transpl Immunol
Journal subject:
Allergy and Immunology
/
Transplantation
Year:
2022
Document Type:
Article
Affiliation country:
J.trim.2022.101600
Similar
MEDLINE
...
LILACS
LIS